Protalix Biotherapeutics Inc (PLX)
Protalix Biotherapeutics Inc. is a biopharmaceutical company focused on developing, producing, and commercializing recombinant therapeutic proteins using its ProCellEx plant cell-based expression system. The company markets Elelyso for Gaucher disease and Elfabrio for adult patients diagnosed with Fabry disease. Its development pipeline includes PRX-115, a plant cell expressed PEGylated uricase in Phase 2 testing for gout, and PRX-119, a PEGylated recombinant human DNase I candidate being studied for neutrophil extracellular traps-related diseases. Protalix has collaboration arrangements with Pfizer, Fundação Oswaldo Cruz, and Chiesi Farmaceutici, and it also maintains a strategic partnership with Secarna Pharmaceuticals GmbH & Co KG. The company operates across the United States, Australia, Canada, Israel, Brazil, Russia, and Turkey, and is headquartered in Hackensack, New Jersey.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NYSE-PLX
|
$2.05
|
-13.1% Downside
|
Fair
|
$11
|
367.1% Upside
|
Bargain
|
Great
|
—
|
—
|
—
|
0.0%
|
August 17, 2026
|
12.4x
|
2.8x
|
2.5x
|
194.2 M
|
147.1 M
|
4.2%
|
96.1%
|
0.4
|
—
|
84.8%
|
